By using the Services, you consent to our use of cookies, web beacons, and similar technologies, including those operated by third parties on our behalf
For people without pre-existing heart conditions, investing in these therapies still proves economically viable according to cardiovascular outcome trialsas shown by their favorable quality-adjusted life year (QALY) figureswhich underscores the broader value of GLP-1 agonists in improving cardiovascular outcomes
Ontario, Canadas most populous province, operates the Ontario Drug Benefit (ODB) program covering eligible residents including seniors, social assistance recipients, and those with high drug costs relative to income
By offering scalable, personalized interventions that empower users to make lasting lifestyle changes, digital health companies can position themselves as key players in the evolving landscape of chronic disease management
or (2) underutilised with a failure to capitalise on the significant glucose-lowering and cardio-renal benefits
Gastroenterology 141, 17921801
